Similar articles

• [Gemfibrozil: new aspects in clinical use].

  Tada N. Tada N. Nihon Rinsho. 2001 Mar;59 Suppl 3:625-30. Nihon Rinsho. 2001. PMID: 11347143 Review. Japanese. No abstract available.
• [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].

  Yoshino G, Hirano T, Kazumi T. Yoshino G, et al. Nihon Rinsho. 2001 Mar;59 Suppl 3:433-5. Nihon Rinsho. 2001. PMID: 11347109 Review. Japanese. No abstract available.
• [Dyslipidemia in renal failure].

  Fujioka T, Ueno T, Matsumoto T, Watanabe H. Fujioka T, et al. Nihon Rinsho. 2004 Jun;62 Suppl 6:118-23. Nihon Rinsho. 2004. PMID: 15250280 Review. Japanese. No abstract available.
• A case for lipid-lowering?

  Durrington P. Durrington P. Diabet Med. 2000 Sep;17 Suppl 2:4-5. doi: 10.1046/j.1464-5491.2000.00361-3.x. Diabet Med. 2000. PMID: 11048824 No abstract available.
• Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.

  Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ. Rustemeijer C, et al. Diabetes Metab Res Rev. 2000 Mar-Apr;16(2):82-7. doi: 10.1002/(sici)1520-7560(200003/04)16:2<82::aid-dmrr89>3.0.co;2-g. Diabetes Metab Res Rev. 2000. PMID: 10751747 Clinical Trial.